Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.

PloS one - 1 Jan 2022

St-Cyr Sophie, Child Daniel D, Giaime Emilie, Smith Alicia R, Pascua Christine J, Hahm Seung, Saiah Eddine, Davidson Beverly L

Abstract excerpt

Huntington's Disease (HD) is a dominantly inherited neurodegenerative disease for which the major causes of mortality are neurodegeneration-associated aspiration pneumonia followed by cardiac failure. mTORC1 pathway perturbations are present in HD models and human tissues. Amelioration of mTORC1 deficits by genetic modulation improves disease phenotypes in HD models, is not a viable therapeutic strategy. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Huntington Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mice, Transgenic

Share to Neurodegenerative Diseases

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 36037192
DOI: 10.1371/journal.pone.0273710
PMCID: PMC9423655

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.PMID 36037192Read ↗

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.Semantic proximity Read ↗

Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's diseaseSemantic proximity Read ↗

The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s DiseaseSemantic proximity Read ↗

Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.Semantic proximity Read ↗

Management and therapy for cardiomyopathy in Friedreich's ataxia.Semantic proximity Read ↗

Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice.Semantic proximity Read ↗

Inhibitors of metabolism rescue cell death in Huntington's disease models.Semantic proximity Read ↗

Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse modelSemantic proximity Read ↗

Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's diseaseSemantic proximity Read ↗

Targeting mutant huntingtin for the development of disease-modifying therapy.Semantic proximity Read ↗

Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.